Recurrent Spindle Cell Carcinoma Shows Features of Mesenchymal Stem Cells
- 1 March 2018
- journal article
- research article
- Published by SAGE Publications in Journal of Dental Research
- Vol. 97 (7) , 779-786
Abstract
This study investigated a case of spindle cell carcinoma (SpCC) in tongue pathological lesions. The patient experienced a local recurrence and distant metastasis after surgical intervention. Although standard chemotherapy was administered, a granulomatous mass continued to develop. This aggressive growth led to survival of the tumor. Secondary debulking surgery was performed to improve the patient’s quality of life at the request of the patient. Using a tissue sample derived from the secondary debulking surgery, we performed an analysis of the tumor’s cell surface antigens, differentiation potential, metastatic ability, and inhibition potential by anticancer reagents. In vitro analysis revealed that the cell population grown under adherent culture conditions expressed the mesenchymal stem cell (MSC) markers CD73, CD90, and CD105. The cell line established from this SpCC contained colony-forming unit fibroblasts (CFU-Fs) and exhibited multipotent differentiation into several mesenchymal lineages, including bone, cartilage, and fat. The SpCC cells also displayed vigorous mobilization. These characteristics suggested that they had the differentiation potential of mesenchymal cells, especially MSCs, rather than that of epithelial cells. The surgical specimen analyzed in this study resisted the molecular target reagent cetuximab, which is an epidermal growth factor receptor inhibitor. This clinical insight revealed that chemotherapy-resistant SpCC cells have different characteristics compared to most other cancer cells, which are sensitive to cetuximab. Our cell death assay revealed that SpCC cell death was induced by the anticancer drug imatinib, which is known to inhibit protein tyrosine kinase activity of ABL, platelet-derived growth factor receptor α (PDGFRα), and KIT. Here, we report recurrent SpCC with characteristics of MSCs and potential for treatment with imatinib.Keywords
This publication has 18 references indexed in Scilit:
- Ectonucleotidase activity and immunosuppression in astrocyte-CD4 T cell bidirectional signalingOncotarget, 2016
- Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell stateeLife, 2014
- Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial–mesenchymal transitionJournal of Cellular and Molecular Medicine, 2013
- LNGFR+THY-1+VCAM-1hi+ Cells Reveal Functionally Distinct Subpopulations in Mesenchymal Stem CellsStem Cell Reports, 2013
- CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc− and Thereby Promotes Tumor GrowthCancer Cell, 2011
- Spindle cell carcinoma of head and neck: an immunohistochemical and molecular approach to its pathogenesisJournal of Clinical Pathology, 2006
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic SyndromeNew England Journal of Medicine, 2003
- Sarcomatoid squamous cell carcinoma of the mucous membranes of the head and neck: A clinicopathologic study of 20 casesCancer, 1981
- Spindle cell carcinoma.Ultrastructural evidence of squamous origin and collagen production by the tumor cellsCancer, 1976